Financials

  • Market Capitalization 1.13 B
  • Employee 161
  • Founded 2002
  • CEO N/A
  • Website www.dbv-technologies.com
  • Headquarter France
  • FIGI BBG0076D3T39
  • Industry Biyoteknoloji
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
-18.26
Fiyat/satışlar oranı
474.74

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

Haberler